News

The Pharma Letter2h
Gilead says Trodelvy ASCENT-03 study meets primary endpoint
US antivirals major Gilead Sciences (Nasdaq: GILD) yesterday released positive top-line results from the Phase III ASCENT-03 ...
The Pharma Letter22h
Reshaping HIV – how the journey from daily pills to long-acting therapies could take us closer to ending the HIV epidemic
Dr Kimberly Smith, Senior Vice President, Chief Scientific Officer, Head of Research & Development at ViiV Healthcare, ...
The Pharma Letter23h
Ionis’ olezarsen shows new promise with strong Phase III results
US biotech Ionis Pharmaceuticals has reported positive top-line data from the Phase III ESSENCE trial of its antisense drug ...